In recent years, anti-PD-L1 immunotherapy has been shown to robustly activate the immune system, produce antitumor immune responses, and improve survival outcomes in patients with various cancers including melanoma and hepatocellular carcinoma [6–8]. Here, CD274 is linked to cancer.